Press Releases ALX Oncology Holdings Inc.

Equities

ALXO

US00166B1052

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-16 pm EDT			5-day change	1st Jan Change
14.66 ^USD	-2.40%		-13.51%	-1.54%

May. 09	ALX Oncology Holdings Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
May. 08	Alx Oncology Holdings Insider Sold Shares Worth $318,334, According to a Recent SEC Filing	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

ALX Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update	May. 09	GL
ALX Oncology Appoints Allison Dillon as Chief Business Officer	May. 07	GL
ALX Oncology Appoints Allison Dillon as Chief Business Officer	May. 07	AQ
ALX Oncology Announces Initiation of Phase 2 Investigator-Sponsored Trial of Neoadjuvant Radiation and Evorpacept in Combination with Pembrolizumab in Patients with Untreated HPV-Mediated Oropharyngeal Cancer	Apr. 30	GL
ALX Oncology Announces Initiation of Phase 2 Investigator-Sponsored Trial of Neoadjuvant Radiation and Evorpacept in Combination with Pembrolizumab in Patients with Untreated HPV-Mediated Oropharyngeal Cancer	Apr. 30	AQ
ALX Oncology Announces Two Evorpacept Abstracts Accepted for Poster Presentation at 2024 ASCO Annual Meeting	Apr. 24	GL
ALX Oncology Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (“R/R B-NHL”)	Apr. 09	GL
ALX Oncology : Corporate Presentation	Mar. 11	PU
ALX Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update	Mar. 07	GL
ALX Oncology Announces Two Evorpacept Clinical Abstracts Accepted for Presentation at the AACR Annual Meeting	Mar. 05	GL
ALX Oncology Announces Two Evorpacept Clinical Abstracts Accepted for Presentation at the AACR Annual Meeting	Mar. 05	AQ
ALX Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference	Jan. 03	GL
ALX Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update	Nov. 13	GL
ALX Oncology Announces November Investor Conference Participation	Nov. 01	GL
ALX Oncology Announces Closing of Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares	23-10-10	GL
ALX Oncology Announces Pricing of Public Offering	23-10-05	GL
ALX Oncology Announces Pricing of Public Offering	23-10-05	AQ
ALX Oncology Announces Proposed Public Offering	23-10-04	GL
ALX Oncology : ASPEN-06 Phase 2 Interim Gastric/GEJ Cancer Data Conference Call	23-10-03	PU
ALX Oncology : Corporate Presentation	23-10-03	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases ALX Oncology Holdings Inc.

Equities

ALXO

US00166B1052

Press Releases

Filters